Proteins and Peptides
29 December 2020
Novo Nordisk files for EU regulatory approval of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes23 December 2020
ABIONYX Initiates a Phase 2a Clinical Trial With CER-001 in Septic Patients at High Risk of Developing Acute Kidney Injury18 December 2020
Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-413 in Patients with Hearing Loss18 December 2020
Nanoform and Herantis partner to look for opportunities to enhance BBB penetration of CDNF and xCDNF molecules18 December 2020
Novo Nordisk files for EU regulatory approval of once-weekly semaglutide 2.4 mg for weight management17 December 2020
Molecular Partners Announces New Clinical Data, Immunomodulation Platform Advances, and Virology Portfolio Strategy16 December 2020
Arecor Limited: First Patient Dosed in Phase I Clinical Trial of Ultra-Concentrated Rapid Acting Insulin Candidate, AT278, for Diabetes16 December 2020
Novo Nordisk to enter phase 3 development in Alzheimer’s disease with oral semaglutide9 December 2020
Lilly’s tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes4 December 2020
Novo Nordisk files for US FDA regulatory approval of once-weekly semaglutide 2.4 mg for weight management4 December 2020
APEIRON Biologics: Patient recruitment completed in Phase II COVID-19 Clinical Trial of APN01News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports